Search the Newsreel

Orbimed Advisors LLC Has $34.93 Million Holdings in uniQure N.V. $QURE

Orbimed Advisors LLC significantly increased its stake in uniQure N.V. ($QURE) by 189.7% in the first quarter, now holding 2.14 million shares valued at $34.93 million. This makes Orbimed Advisors LLC a 3.39% owner of uniQure, with institutional investors collectively owning 78.83% of the …

Kalehua Capital Management LLC Makes New Investment in uniQure N.V. $QURE

Kalehua Capital Management LLC has made a new investment in uniQure N.V., purchasing 291,109 shares valued at approximately $4.76 million, making it their 11th largest position. Despite insider selling totaling around $17.9 million over the past 90 days, institutional ownership remains high at 78.83%. …

uniQure N.V. Revenue Breakdown – FWB:UQ1

uniQure N.V. (FWB: UQ1) reported its revenue breakdown, showing that the company generated 13.71 million EUR last year. The majority of this revenue came from its top-performing segment, Innovative Gene Therapies, which accounted for the entire 13.71 million EUR, a decrease from 26.20 million …

Mayur Uniquoters Limited Revenue Breakdown – NSE:MAYURUNIQ

uniQure (QURE) to Release Earnings on Wednesday

uniQure (NASDAQ:QURE) is scheduled to release its Q2 2026 earnings before market open on Wednesday, July 29th. Analysts anticipate a loss of $0.8223 per share and revenue of $5.449 million. Despite mixed results in the previous quarter, with EPS beating estimates but revenue falling …

Earnings Preview: UniQure NV to Report Financial Results Pre-market on July 29

UniQure NV (NASDAQ: QURE) is scheduled to announce its financial results before market open on July 29. Investors will be looking for an earnings per share (EPS) of -$0.69, a significant increase from the -$0.98 reported in the same quarter last year, and revenue …

uniQure N.V. to announce Q2 2026 financial results on July 29

uniQure N.V. (NASDAQ: QURE) is scheduled to release its second-quarter 2026 financial results before market open on Wednesday, July 29, 2026, followed by a conference call at 8:30 a.m. ET. The company will discuss financial outcomes and operational updates regarding its gene therapy pipeline, …

uniQure sets July 29 webcast after Q2 financial results

Aberdeen Group plc (QURE) discloses 2.85M-share, 4.52% holding in uniQure

Aberdeen Group plc and its subsidiary abrdn Inc. have disclosed an updated passive ownership stake in uniQure N.V. (QURE) through an Amendment No. 4 to Schedule 13G. As of June 30, 2026, they beneficially own 2,848,117 ordinary shares, which constitutes 4.52% of the outstanding …

uniQure NV | 144: Notice of proposed sale of securities pursuant to Rule 144

This document is a formal Notice of Proposed Sale of Securities pursuant to Rule 144 for uniQure NV. It indicates an intention to sell securities under specific conditions designed to ensure liquidity for restricted and control securities. Further details regarding the nature and volume …

uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix

uniQure (QURE) is evolving beyond its single program gene therapy, Hemgenix, by focusing on faster regulatory pathways, streamlining its operations, and expanding into rare neurological diseases. The company's Huntington's disease gene therapy, AMT-130, has received multiple FDA designations, suggesting a quicker path to approval, …

UniQure (QURE) now trades above golden cross: Time to buy?

This article discusses the recent technical indicator of UniQure (QURE) trading above its golden cross. It suggests that this development could be a strong signal for investors to consider buying the stock, indicating potential upward momentum. The content likely examines the implications of this …

QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway

uniQure (QURE) is primarily driven by its gene therapy candidate, AMT-130, for Huntington’s disease, with a potential biologics license application submission in Q3 2026 and a cash runway extending into late 2029. Recent positive feedback from the FDA on a clearer regulatory path for …

Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold?

uniQure N.V. (QURE) stock has seen a significant rally due to renewed investor interest in its lead gene therapy candidate, AMT-130, for Huntington's disease. Despite positive earnings surprises and a strong cash position that funds operations into 2029, the stock's valuation is considered rich, …

JPMorgan discloses 7% uniQure (QURE) stake of 4,866,211 shares

JPMorgan Chase & Co. has filed a Schedule 13G, disclosing a beneficial ownership of 4,866,211 Ordinary Shares in uniQure N.V. (QURE), which represents a 7.0% stake in the company. JPMorgan holds sole voting power over 4,598,521 shares and sole dispositive power over 4,866,201 shares. …

Mayur Uniquoters accepts resignation of senior manager

Price to earnings forward of uniQure N.V. – NASDAQ:QURE

Mayur Uniquoters Limited Actuals & Estimates (NSE:MAYURUNIQ)

MAYURUNIQ Forecast — Price Target — Prediction for 2027

uniQure (NASDAQ: QURE) files Rule 144 resale notice listing recent insider sales

QURE Stock Soars As FDA Boosts Gene Therapy Outlook

Does Mayur Uniquoters (NSE:MAYURUNIQ) Deserve A Spot On Your Watchlist?

Mayur Uniquoters FY26 Net Profit Rises 43%; Dividend Declared

Considering Uniqure NV (QURE) Stock? Read the AMT-130 Message

Mayur Uniquoters Dhodsar Strike Resolved; Plant Fully Operational After Rs. 1.50 Crore Revenue Loss

UniQure Q1 Earnings Review: Limited Progress With FDA, But UK Approval In Play

Mayur Uniquoters Limited Submits SEBI Depositories Certificate for Q4FY26

UNIX มั่นใจเข้าเทรดวันแรกใน SET กระแสตอบรับดีเยี่ยม ชูจุดเด่นหุ้นไฮบริด คุณสมบัติ Growth - Dividend Stock ลุยพัฒนานวัตกรรมพลาสติกรักษ์โลกรีไซเคิลได้100% สอดรับเทรนด์ความยั่งยืน - มิติหุ้น | ชี้ชัดทุกการลงทุน

Mayur Uniquoters Promoter Kiran Poddar Increases Stake with Fresh Acquisition

UNIQURE ($QURE) Releases Q4 2025 Earnings | QURE Stock News

Mayur Uniquoters Appoints Puja Poddar as President-HR and Administration

Mayur Uniquoters Expects Strong Export Growth to Outpace Domestic Expansion

Mayur Uniquoters Evaluates ₹200-300 Crore Capital Expenditure for New PVC Plant

Mayur Uniquoters Reports Robust Q2 Performance with 16% Profit Growth

uniQure NV (QURE) Q3 2025 Earnings Call Highlights: Promising Data Amid Regulatory Challenges

Harga Saham UNIQ Hari Ini - Ulima Nitra Tbk. = Rp111